Stocks Health care HCWB
NASDAQ · Health careHCW Biologics Inc. (HCWB)
HCW Biologics Inc. brought in $6.7M of revenue over the twelve months to June 30, 2026, up 707.0% from a year earlier. It posted a net loss of $5.6M. In fiscal 2025 capital spending exceeded operating cash flow by $13.4M. At June 30, 2026 it held $741.3K in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.
Key facts about HCW Biologics Inc.
- Net worth
- HCW Biologics Inc. has a market value (market cap) of $1.7M at the latest share price, and shareholders' equity of $7.4M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $54.2K (-97.9% year on year), with a net loss of $8M. Over the 12 months to June 30, 2026: revenue $6.7M, net loss $5.6M.
- Cash flow
- In fiscal 2025 operations used $13.4M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 14, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- HCW Biologics Inc.'s next report was expected around October 21, 2026 and is not on file with the SEC yet.
What HCW Biologics Inc. does
HCW Biologics Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker HCWB.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $54.2K | -$8M | -$10.63 | -$13.4M |
| 2024 | $2.6M | -$30M | -$30.96 | -$14.5M |
| 2023 | $2.8M | -$25M | -$28.15 | -$28.7M |
| 2022 | $6.7M | -$14.9M | -$16.89 | -$20.7M |
| 2021 | $0 | -$12.9M | -$27.74 | -$11M |
| 2021 | $4.1M | -$5.8M | -$59.91 | -$10.6M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where HCWB ranks in Health care
Latest SEC filings
What HCW Biologics Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 2, 2026IPO registration S-1
- October 1, 2026Proxy statement DEF 14A
- September 24, 2026Material agreement8-KHCW Biologics agreed to raise approximately $1.5 million in a private placement with an existing institutional investor.
- September 10, 2026
- September 9, 2026Form PRER14A filing PRER14A
- September 8, 2026
- September 8, 2026Preliminary proxy statement PRE 14A
- August 28, 2026
- August 20, 2026IPO registration S-1
- August 14, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 1,970% to $135.6K versus the same quarter last year; diluted EPS -$11.58 versus -$40.72.
Insider trades
What the people running HCW Biologics Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| July 29, 2026 | Garrett Scott TDirector | Boughtindirect | 7,736 | $20K |
| July 29, 2026 | Flowers LeeSVP of Business Development | Bought | 7,736 | $20K |
| July 29, 2026 | Wong Hing CChief Executive Officer, Director, 10% owner | Bought | 23,210 | $60K |
| May 22, 2026 | Byam RebeccaChief Financial Officer | Bought | 14,235 | $20K |
| May 22, 2026 | Garrett Scott TDirector | Boughtindirect | 177,936 | $250K |
| May 22, 2026 | Wong Hing CChief Executive Officer, Director, 10% owner | Bought | 113,879 | $160K |
Who owns HCWB
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Hing C. Wong13D, may seek influence | 36.04% | November 22, 2024 |
| Hing C. Wong, Ph.D.13D, may seek influence | 23.38% | June 13, 2025 |
Largest institutional holders
Insiders
4 insiders reported holding 233,425 shares in total, about $221.8K at the last price.
| Holder | Shares |
|---|---|
| Wong Hing CChief Executive Officer, Director, 10% owner | 125,845 |
| Byam RebeccaChief Financial Officer | 57,245 |
| Garrett Scott TDirector | 41,64441,644 held indirectly |
| Flowers LeeSVP of Business Development | 8,691 |
Questions about HCWB
What does HCW Biologics Inc. do?
HCW Biologics Inc. is a company in the Health care sector, listed on NASDAQ as HCWB. Its shares trade on NASDAQ under the ticker HCWB.
What is HCW Biologics Inc.'s net worth?
HCW Biologics Inc. has a market value (market cap) of $1.7M at the latest share price, and shareholders' equity of $7.4M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is HCW Biologics Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $5.6M on revenue of $6.7M.
How much revenue does HCW Biologics Inc. make?
Over the twelve months to June 30, 2026 HCW Biologics Inc. reported revenue of $6.7M. That is 707.0% more than a year earlier.
When did HCW Biologics Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the iPO registration from October 2, 2026.
When is HCW Biologics Inc.'s next earnings report?
HCW Biologics Inc.'s next report was expected around October 21, 2026 and is not on file with the SEC yet.
Similar companies
Compare HCWB with
Follow HCWB
Get an email when HCW Biologics Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values HCW Biologics Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.